Clinical trials: Multiple Sclerosis, Relapsing-Remitting
Relapsing-remitting Multiple Sclerosis (rrMS)
Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).
To evaluate the safety, bio-distribution, and radiation dosimetry; and to optimize the Imaging Protocol of GEH120714 (18F) Injection.
- Trial name
- NCT01738347
- Testing
- Arm 1 - GEH120714 (18F) Injection
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Relapsing-remitting Multiple Sclerosis
Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis
There are two standard and a few second line treatments for RRMS. Since the disease cannot be cured by these existing treatments and all treatment options have significant limitations, there is the need to develop new treatment…
- Trial name
- RESI (NCT02364986)
- Testing
- Rebif®, Avonex
- Where
- 2 sites in Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- PD Dr. Marcus Müller
Multiple Sclerosis - Relapsing Remitting, Clinically Isolated Syndrome, CNS Demyelinating
DTI in Children With Multiple Sclerosis
This is a prospective, non-randomised, non-blinded, single center study of children and adolescents with multiple sclerosis and clinically isolated syndrome to detect differences or early changes in diffusion-weighted imaging…
- Trial name
- NCT02361697
- Testing
- DTI-MRI
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Hospital Muenster
Multiple Sclerosis, Relapsing-Remitting
Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis.
HLA-DRB1 * Gene and some genes involved in inflammation and immunity (IL-7R, GPC5, CTSS) have been linked to risk of MS and the response to treatment with immunomodulators.
- Trial name
- WESTEMDRB1 (NCT02769767)
- Testing
- Polymorphism of Interleukins, Glypican, and Human Leukocyte Antigen Genes.
- Where
- Mexico
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Instituto Jalisciense de Cancerologia
Relapsing Remitting Multiple Sclerosis
High Dose Oral Versus Intramuscular Vitamin D3 Supplementation In Multiple Sclerosis Patients
This study aimed to evaluate oral and injectable routes in treatment of hypovitaminosis D in multiple sclerosis (MS) patients. The investigators aimed to assess the efficacy of each method, using the same Mega dose of 600 000 IU…
- Trial name
- NCT02696590
- Testing
- Vitamin D3
- Where
- Iran
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Isfahan University of Medical Sciences
Multiple Sclerosis, Relapsing-Remitting
Phase I BP Interferon (IFN) Beta-004
Phase I study aiming at: establishing the pharmacokinetic profile of interferon beta-1a after i.v. administration of the formulation BioPartners IFN beta-1a without albumin (HSA-free solution in pre-filled syringes) at 18 MIU…
- Trial name
- NCT02517788
- Testing
- Interferon beta-1a HSA-free biosimilar, Interferon beta-1a HSA+ biosimilar, Interferon beta-1a original
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Multiple Sclerosis, Relapsing-Remitting
Phase I BP Interferon (IFN) Beta-001
Phase I study aiming at: assessing the absolute bioavailability, pharmacokinetic profile, and dose proportionality of interferon beta-1a (HSA-free solution in pre-filled syringes) after i.v. and s.c.
- Trial name
- NCT02515695
- Testing
- Interferon beta-1a
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Relapsing-remitting Multiple Sclerosis
Mass Balance Study of MT-1303
The purpose of this study is to investigate the absorption, metabolism and excretion of MT-1303 in healthy subjects.
- Trial name
- NCT02293967
- Testing
- MT-1303
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Relapsing-remitting Multiple Sclerosis
Comparative Oral Bioavailability Study of MT-1303
The purpose of this study is to assess the comparative oral bioavailability of a Formulation B versus the Formulation A of MT-1303.
- Trial name
- NCT02310048
- Testing
- MT-1303-FormA, MT-1303-FormB
- Where
- United Kingdom
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Relapsing-remitting Multiple Sclerosis
A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303
The purpose of this study is to explore the cardiac pharmacodynamics, safety and tolerability of MT-1303 in healthy subjects.
- Trial name
- NCT02193217
- Testing
- MT-1303-Low, MT-1303-High, Fingolimod
- Where
- United Kingdom
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Relapsing-Remitting Multiple Sclerosis
fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls
Impaired short term memory, attention and concentration lapses, and slower processing of information occur in up to 40-65% of patients with Multiple Sclerosis (MS).
- Trial name
- NCT00391352
- Testing
- IFN-β-1a (Rebif®)
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Waukesha Memorial Hospital
Relapsing Remitting Multiple Sclerosis
Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)
People with multiple sclerosis (MS) often experience problems with cognitive functioning, which can be debilitating and interfere with their daily functioning.
- Trial name
- NCT00914758
- Where
- 7 sites in United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Washington Neuropsychology Research Group